Great Place to Work® and FORTUNE name Roche Diagnostics one of the Best Workplaces for Millennials

News provided by

Jun 27, 2017, 13:33 ET

INDIANAPOLIS, June 27, 2017 /PRNewswire/ -- Roche Diagnostics was named as #67 on the list of the country's Best Workplaces for Millennials, announced by research and consulting firm Great Place to Work and FORTUNE.

The ranking considered 398,000 surveys that assessed organizations' fairness, teamwork, benefits and other elements essential to an outstanding work culture.

Millennials at Roche can take advantage of early in career workshops and participate in a a variety of business resource groups that support their development.

"Roche Diagnostics is proud to be recognized by FORTUNE for being among the top employers for early-in-career talent," said Bridget Boyle, VP & Site Head Human Resources, Roche Diagnostics. "With 50 million millennials being hired between now and 2025, we're focused on new ways to engage this demographic in order to attract, develop and retain top talent."

While many companies report high turnover among younger workers, an average of 85 percent of millennial front-line employees at the Best Workplaces say they want to work at their organizations for a long time.

"Millennials expect more from their employers in areas like fair treatment, clear communication, authentic leadership and opportunities for advancement – and rightly so. The Best Workplaces for Millennials are finding that fulfilling all these expectations by building a high-trust culture boosts millennial employees' intent to stay by 20 times," said Michael Bush, CEO of Great Place to Work.

The Best Workplaces for Millennials is one of a series of rankings by Great Place to Work and FORTUNE based on employee feedback from Great Place to Work–Certified™ organizations. Roche Diagnostics was also ranked as a Best Workplace for Health Care by Great Place to Work and FORTUNE.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-eight medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For additional information, please contact:

Christina Vysma
Communications Partner
Roche Diagnostics Corporation
Indianapolis, Indiana USA
(317) 292-2920

SOURCE Roche